Literature DB >> 19409210

Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells.

Z Kawakami1, H Kanno, T Ueki, K Terawaki, M Tabuchi, Y Ikarashi, Y Kase.   

Abstract

To clarify the mechanism of yokukansan (TJ-54), a traditional Japanese medicine, against glutamate-mediated excitotoxicity, the effects of TJ-54 on glutamate uptake function were first examined using cultured rat cortical astrocytes. Under thiamine-deficient conditions, the uptake of glutamate into astrocytes, and the levels of proteins and mRNA expressions of glutamate aspartate transporter of astrocytes significantly decreased. These decreases were ameliorated in a dose-dependent manner by treatment with TJ-54 (100-700 microg/ml). The improvement of glutamate uptake with TJ-54 was completely blocked by the glutamate transporter inhibitor DL-threo-beta-hydroxyaspartic acid. Effects of TJ-54 on glutamate-induced neuronal death were next examined by using cultured PC12 cells as a model for neurons. Addition of 17.5 mM glutamate to the culture medium induced an approximately 50% cell death, as evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. TJ-54 (1-1000 microg/ml) inhibited the cell death in a dose-dependent manner. Furthermore, competitive binding assays to glutamate receptors showed that TJ-54 bound potently to N-methyl-D-aspartate receptors, in particular, to its glutamate and glycine recognition sites. These results suggest that TJ-54 may exert a neuroprotective effect against glutamate-induced excitotoxicity not only by amelioration of dysfunction of astrocytes but also by direct protection of neuronal cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409210     DOI: 10.1016/j.neuroscience.2009.02.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Mother/offspring co-administration of the traditional herbal remedy yokukansan during the nursing period influences grooming and cerebellar serotonin levels in a rat model of neurodevelopmental disorders.

Authors:  Katsumasa Muneoka; Makiko Kuwagata; Tetsuo Ogawa; Seiji Shioda
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

3.  Effect of Yokukansan for the Treatment of Idiopathic Rapid Eye Movement Sleep Behavior Disorder: A Retrospective Analysis of Consecutive Patients.

Authors:  Kentaro Matsui; Taeko Sasai-Sakuma; Jun Ishigooka; Katsuji Nishimura; Yuichi Inoue
Journal:  J Clin Sleep Med       Date:  2019-08-15       Impact factor: 4.062

4.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

5.  Yokukansan Reduces Cuprizone-Induced Demyelination in the Corpus Callosum Through Anti-inflammatory Effects on Microglia.

Authors:  Taichi Nomura; Yoshio Bando; Hua You; Tatsuhide Tanaka; Shigetaka Yoshida
Journal:  Neurochem Res       Date:  2017-09-19       Impact factor: 3.996

6.  Effects of yokukansan on anxiety-like behavior in a rat model of cerebrovascular dementia.

Authors:  Ai Nogami; Yuri Sakata; Naoki Uchida; Kazuko Yamaguchi; Chihiro Kawasaki; Taro Shindo; Kaori Kubota; Shutaro Katsurabayashi; Kotaro Takasaki; Kenichi Mishima; Ryoji Nishimura; Michihiro Fujiwara; Katsunori Iwasaki
Journal:  J Nat Med       Date:  2010-12-09       Impact factor: 2.343

7.  Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan.

Authors:  Zenji Kawakami; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2011-06-21       Impact factor: 5.046

8.  The blood-brain barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan.

Authors:  Masahiro Tabuchi; Sachiko Imamura; Zenji Kawakami; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2012-04-10       Impact factor: 5.046

9.  The Kampo medicine Yokukansan (YKS) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.

Authors:  Kazuki Terada; Yukari Matsushima; Kazuhisa Matsunaga; Jiro Takata; Yoshiharu Karube; Atsushi Ishige; Koji Chiba
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

10.  Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials.

Authors:  M Seibert; V Mühlbauer; J Holbrook; S Voigt-Radloff; S Brefka; D Dallmeier; M Denkinger; C Schönfeldt-Lecuona; S Klöppel; C A F von Arnim
Journal:  Alzheimers Res Ther       Date:  2021-07-16       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.